FY2025 · ended Dec 31, 2025 · Revenue $6.44M, -78.3% YoY · Filed Mar 16, 2026
Kyntra Bio, Inc. (KYNB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $6.4 million and net income of $183.5 million. Free cash flow was -$4.8 million. As of Jun 30, 2026 it held $95.3 million in cash and investments and $75.0 million in total debt.
Revenue (TTM)
$4.62M
-37.2% vs year-ago TTM
Net income (TTM)
$183.19M
+8967.0% vs year-ago TTM
Operating cash flow (TTM)
$-38.05M
-62.3% vs year-ago TTM
Free cash flow (TTM)
$-38.06M
-60.6% vs year-ago TTM
EPS (TTM)
$45.27
+8938.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.05M
-96.0% vs prior year
Net cash
$20.33M
as of Jun 30, 2026
Operating margin
-1090.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KYNB (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 921299
- Former names
- FIBROGEN INC (until Jan 7, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.4M | $29.6M | $46.8M | $140.7M | $235.3M |
| Operating income | -$45.9M | -$150.4M | -$322.7M | -$301.0M | -$288.5M |
| Net income | $183.5M | -$47.6M | -$284.2M | -$293.7M | -$290.0M |
| Diluted EPS | $45.37 | -$11.89 | -$2.92 | -$3.14 | — |
| Operating cash flow | -$4.8M | -$138.0M | -$315.0M | -$145.9M | -$82.2M |
| Free cash flow | -$4.8M | -$138.3M | -$317.5M | -$149.7M | -$87.4M |
| Total assets | $119.6M | $214.5M | $423.5M | $610.1M | $773.8M |
| Total liabilities | $115.1M | $398.2M | $585.7M | $611.6M | $544.7M |
| Stockholders' equity | -$30.0M | -$225.6M | -$204.2M | -$21.4M | $209.1M |
| Cash and investments | $109.1M | $50.5M | $203.5M | $422.0M | $405.2M |
| Total debt | — | $104,000 | $80.8M | $90.1M | $99.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 1, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 12, 2026 |
All 1000 Kyntra Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.